Sarepta seems confident that despite the missed primary endpoint, it can still achieve that objective. Roche acquired commercial rights to Elevidys outside the US under a 2019 deal with Sarepta ...

Sarepta already markets three drugs for DMD that have to be taken chronically, but SRP-9001 offers the possibility of a one-shot therapy for the disease. Roche has exclusive rights to the therapy ...

Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

Read Our Latest Stock Report on SRPT Sarepta Therapeutics Stock Down 0.3 % Shares of NASDAQ SRPT opened at $111.82 on Thursday. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high ...

Arrowhead (ARWR) announced that the global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was ...

Dyne Therapeutics Inc.-5.60% $1.56B ...